PMCB - PharmaCyte Biotech uplisted to Nasdaq prices $15M offering

PharmaCyte Biotech (OTCQB:PMCB) common stock expected to begin trading on Nasdaq on August 10, 2021, under the symbol “PMCB.” Company also announced the pricing of its previously announced underwritten public offering of ~3.53M shares. Each share of common stock is being sold together with one warrant to purchase one share of common stock at an effective combined public offering price of $4.25 per share of common stock and accompanying warrant, less underwriting discounts and commissions.  Gross proceeds of ~$15M.

For further details see:

PharmaCyte Biotech uplisted to Nasdaq, prices $15M offering